國家衛生研究院 NHRI:Item 3990099045/12626

NHRI > National Institute of Infectious Diseases and Vaccinology > Hsin-Wei Chen > Periodical Articles > Item 3990099045/12626

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12626

Title:	Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice
Authors:	Chen, MY;Chai, KM;Chiang, CY;Wu, CC;Yu, GY;Liu, SJ;Chen, HW
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	BACKGROUND: The emergence of Zika virus (ZV) in tropical and subtropical areas of the world has created an urgent need for vaccines against ZV. However, approved vaccines that prevent ZV infection are not available. To develop an effective vaccine against ZV infection, a lipidated form of ZV envelope protein domain III that possesses an intrinsic adjuvant property was rationally designed. Our goal was to examine the immunogenicity of recombinant lipidated ZV envelope protein domain III (rLZE3) and evaluate its potential as a vaccine candidate against ZV. METHODS: Recombinant ZV envelope protein domain III (rZE3) and rLZE3 were prepared with an Escherichia coli-based system. Dendritic cell surface marker expression and cytokine production upon stimulation were analyzed to evaluate the function of rLZE3. Neutralizing antibody capacities were evaluated using focus reduction neutralization tests after immunization. To investigate the protective immunity in immunized mice, serum samples collected from immunized mice were adoptively transferred into AG129 mice, and then viremia levels and survival times were examined after ZV challenge. RESULTS: rLZE3 alone but not rZE3 alone efficiently activated dendritic cells in vitro and was taken up by dendritic cells in vivo. Immunization of C57BL/6 mice with rLZE3 alone (without exogenous adjuvant) could induce ZV-specific neutralizing antibody responses. Furthermore, serum samples obtained from rLZE3-immunized mice provided protection as indicated by a reduction in viremia levels and prolongation of survival times after ZV challenge. CONCLUSION: These results indicate that rLZE3 is an excellent vaccine candidate and has great potential that should be evaluated in further preclinical studies.
Date:	2020-04-14
Relation:	Journal of Biomedical Science. 2020 Apr 14;27:Article number 51.
Link to:	http://dx.doi.org/10.1186/s12929-020-00646-x
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1021-7770&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000528674500001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85083408101
Appears in Collections:	[Hsin-Wei Chen] Periodical Articles [Shih-Jen Liu] Periodical Articles [Guann-Yi Yu] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB32290844.pdf		1686Kb	Adobe PDF	344	View/Open

Loading...